This reduced approach allowed us to quantitatively explore the roles of CAR and HER2 (CAR antigen) abundances, CAR affinities, and the ensuing cell signaling in regulating CAR T cell responses against healthy and tumor cells. The gene discussed is ERBB2; the disease is neoplasm.